Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap

Source Summary

New scientific data reveal serious shortcomings in the real-world management of anaphylaxis, with findings from two multi-country surveys suggesting that EUR neffy ® —the first and only approved needle-free adrenaline-based product—may help address some of the practical and psychological challenges that limit effective emergency treatment in daily life. 1,2 The data generated by ALK were presented at the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress in Istanbul, Turkey.